Switch theme
Sign up to access all valuation multiples
RTW Biotech Opportunities Ltd is an investment fund focused on identifying transformative assets with growth potential across the life sciences sector. Its approach is driven by applying deep scientific expertise with a long-term investment horizon. Geographically, it operates in U.S. &Canada, UK & EU, and Rest of the world.
2017
n/a
Last FY Revenue $38.7M
Last FY EBITDA n/a
$413M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, RTW Biotech Opportunities achieved revenue of $38.7M and an EBITDA of n/a.
RTW Biotech Opportunities expects next 12-month revenue of XXX and NTM EBITDA of XXX
See RTW Biotech Opportunities valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $38.7M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | n/a | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | $34.2M | XXX | XXX | XXX |
| Net Margin | XXX | 88% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 16, 2025, RTW Biotech Opportunities's stock price is $1.
RTW Biotech Opportunities has current market cap of $413M, and EV of $413M.
See RTW Biotech Opportunities trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $413M | $413M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 16, 2025, RTW Biotech Opportunities has market cap of $413M and EV of $413M.
RTW Biotech Opportunities's trades at 10.7x EV/Revenue multiple, and n/a EV/EBITDA.
Equity research analysts estimate RTW Biotech Opportunities's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
RTW Biotech Opportunities's P/E ratio is not available.
See valuation multiples for RTW Biotech Opportunities and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $413M | XXX | $413M | XXX | XXX | XXX |
| EV (current) | $413M | XXX | $413M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 10.7x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 12.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRTW Biotech Opportunities's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
RTW Biotech Opportunities's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
RTW Biotech Opportunities's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for RTW Biotech Opportunities and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 12% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| XXX | XXX | XXX | XXX | XXX | XXX | |
| Waha Capital | XXX | XXX | XXX | XXX | XXX | XXX |
| CVC Capital Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| EXOR | XXX | XXX | XXX | XXX | XXX | XXX |
| Pengana Private Equity | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
RTW Biotech Opportunities acquired XXX companies to date.
Last acquisition by RTW Biotech Opportunities was XXXXXXXX, XXXXX XXXXX XXXXXX . RTW Biotech Opportunities acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was RTW Biotech Opportunities founded? | RTW Biotech Opportunities was founded in 2017. |
| Where is RTW Biotech Opportunities headquartered? | RTW Biotech Opportunities is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| Is RTW Biotech Opportunities publicy listed? | Yes, RTW Biotech Opportunities is a public company listed on LON. |
| What is the stock symbol of RTW Biotech Opportunities? | RTW Biotech Opportunities trades under RTW ticker. |
| Who are competitors of RTW Biotech Opportunities? | Similar companies to RTW Biotech Opportunities include e.g. , Waha Capital, CVC Capital Partners, EXOR. |
| What is the current market cap of RTW Biotech Opportunities? | RTW Biotech Opportunities's current market cap is $413M |
| Is RTW Biotech Opportunities profitable? | Yes, RTW Biotech Opportunities is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
